Aclimostat – (2082752-83-6)

Aclimostat, also known as ZGN-1061, is an experimental drug developed by Zafgen for the treatment of obesity and type 2 diabetes. It functions as a potent inhibitor of the enzyme MetAP2 (methionine aminopeptidase 2).

In preclinical studies, Aclimostat demonstrated efficacy comparable to beloranib for weight loss and improvements in metabolic parameters in mouse models of obesity and insulin resistance.

Additionally, it showed concordant changes in gene transcription in HepG2 cells. Despite its promising efficacy, the development of Aclimostat was halted due to safety concerns, similar to its predecessor, beloranib.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/ZGN-1061
https://pubchem.ncbi.nlm.nih.gov/compound/126573394
https://www.medchemexpress.com/aclimostat.html
https://www.medkoo.com/products/29238
https://www.sciencedirect.com/org/science/article/pii/S1568009623000046